Common Drug Alcohol Interactions

  • ACETAMINOPHEN – Concurrent use of ACETAMINOPHEN and ETHANOL may result in an increased risk of hepatotoxicity.
  • ACETOPHENAZINE – Concurrent use of ACETOPHENAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • ACITRETIN – Concurrent use of ACITRETIN and ETHANOL may result in a prolonged risk of teratogenicity.
  • ALFENTANIL – Concurrent use of ALFENTANOL and ETHANOL may result in decreased therapeutic effects for Alfentanil.
  • ALPRAZOLAM – Concurrent use of ALPRAZOLAM and ETHANOL may result in increased sedation.
  • AMITRIPTYLINE – Concurrent use of AMITRIPTYLINE and ETHANOL may result in enhanced CNS depression and impairment of motor skills.
  • AMOBARBITAL – Concurrent use of AMOBARBITAL and ETHANOL may result in excessive CNS depression.
  • AMOXAPINE – Concurrent use of AMOXAPINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • AMPRENAVIR – Concurrent use of AMPRENAVIR and ETHANOL may result in an increased risk of propylene glycol toxicity (seizures, tachycardia, lactic acidosis, renal toxicity, and hemolysis).
  • APROBARBITAL – Concurrent use of APROBARBITAL and ETHANOL may result in excessive CNS depression.
  • ASPIRIN – Concurrent use of ASPIRIN and ETHANOL may result in increased gastrointestinal blood loss.
  • ATORVASTATIN – Concurrent use of ATORVASTATIN and ETHANOL may cause liver problems.
  • BUPROPION – Concurrent use of BUPROPION and ETHANOL may result in an increased risk of seizures.
  • BUTABARBITAL – Concurrent use of BUTABARBITAL and ETHANOL may result in excessive CNS depression.
  • BUTALBITAL – Concurrent use of BUTALBITAL and ETHANOL may result in excessive CNS depression.
  • CALAMUS – Concurrent use of CALAMUS and ETHANOL may result in increased sedation.
  • CANNABIS – Concurrent use of CANNABIS and ETHANOL may result in increased intoxication.
  • CARVEDILOL PHOSPHATE – Concurrent use of CARVEDILOL, PHOSPHATE and ETHANOL may result in faster than normal rate of release of carvedilol phosphate.
  • CEFAMANDOLE – Concurrent use of CEFAMANDOLE and ETHANOL may result in disulfiram-like reactions.
  • CEFMENOXINE – Concurrent use of CEFMENOXINE and ETHANOL may result in disulfiram-like reactions.
  • CEFOPERAZONE – Concurrent use of CEFOPERAZONE and ETHANOL may result in disulfiram-like reactions.
  • CEFOTETAN – Concurrent use of CEFOTETAN and ETHANOL may result in disulfiram-like reactions.
  • CHAPARRAL – Concurrent use of CHAPARRAL and ETHANOL may result in elevated liver transaminases with or without concomitant hepatic damage.
  • CHLORAL HYDRATE – Concurrent use of CHLORAL HYDRATE and ETHANOL may result in increased sedation.
  • CHLORDIAZEPOXIDE – Concurrent use of CHLORDIAZEPOXIDE and ETHANOL may result in increased sedation.
  • CHLORPROMAZINE – Concurrent use of CHLORPROMAZINE and ETHANOL may result in increased sedation.
  • CHLORPROPAMIDE – Concurrent use of CHLORPROPAMIDE and ETHANOL may result in disulfiram-like reactions.
  • CIMETIDINE – Concurrent use of CIMETIDINE and ETHANOL may result in increased ethanol concentrations.
  • CISAPRIDE – Concurrent use of CISAPRIDE and ETHANOL may result in increased blood levels of ethanol.
  • CITALOPRAM – Concurrent use of CITALOPRAM and ETHANOL may result in potentiation of the cognitive and motor effects of alcohol.
  • CLOMIPRAMINE – Concurrent use of CLOMIPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • CLORAZEPATE – Concurrent use of CLORAZEPATE and ETHANOL may result in increased sedation.
  • COCAINE – Concurrent use of COCAINE and ETHANOL may result in increased heart rate and blood pressure.
  • CODEINE – Concurrent use of CODEINE and ETHANOL may result in increased sedation.
  • COMFREY – Concurrent use of COMFREY and ETHANOL may result in elevated inner transaminases with or without concomitant hepatic damage.
  • CYCLOSERINE – Concurrent use of CYCLOSERINE and ETHANOL may result in an increased risk of seizures.
  • DEFLAZACORT – Concurrent use of DEFLAZACORT and ETHANOL may result bleeding & ulcers in the stomach.
  • DESIPRAMINE – Concurrent use of DESIPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • DIAZEPAM – Concurrent use of DIAZEPAM and ETHANOL may result in increased sedation.
  • DIMETHINDENE – Concurrent use of DIMETHINDENE and ETHANOL may result in increased sedation.
  • DIPHENHYDRAMINE – Concurrent use of DIPHENHYDRAMINE and ETHANOL may result in increased sedation.
  • DISULFIRAM – Concurrent use of DISULFIRAM and ETHANOL may result in ethanol intolerance.
  • DOTHIEPIN – Concurrent use of ETHANOL and DOTHIEPIN may result in enhanced drowsiness and impairment of motor skills.
  • DOXEPIN – Concurrent use of DOXEPIN and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • EMPAGLIFLOZIN – Concurrent use of EMPAGLIFLOZIN and ETHANOL may result hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) depending on how much and how often you drink.
  • ESCITALOPRAM – Concurrent use of ESCITALOPRAM and ETHANOL may result in potentiation of the cognitive and motor effects of alcohol.
  • ESZOPICLONE – Concurrent use of ESZOPICLONE and ETHANOL may result in impaired psychomotor functions and risk of increased sedation.
  • ETEROBARB – Concurrent use of ETEROBARB and ETHANOL may result in excessive CNS depression.
  • ETHOPROPAZINE – Concurrent use of ETHOPROPAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • ERTUGLIFLOZIN – Concurrent use of ERTUGLIFLOZIN and ETHANOL may result low blood sugar and a high ketone level.
  • FLUNITRAZEPAM – Concurrent use of FLUNITRAZEPAM and ETHANOL may result in excessive sedation and psychomotor impairment.
  • FLUPHENAZINE – Concurrent use of FLUPHENAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • FOMEPIZOLE – Concurrent use of FOMEPIZOLE and ETHANOL may result in the reduced elimination of both drugs.
  • FOSPHENYTOIN – Concurrent use of FOSPHENYTOIN and ETHANOL may result in decreased phenytoin serum concentrations, increased seizure potential, and additive CNS depressant effects.
  • FURAZOLIDONE – Concurrent use of FURAZOLIDONE and ETHANOL may result in disulfiram-like reactions.
  • GERMANDER – Concurrent use of GERMANDER and ETHANOL may result in elevated liver transaminases with or without concomitant hepatic damage.
  • GLIPIZIDE – Concurrent use of GLIPIZIDE and ETHANOL may result in prolonged hypoglycemia and disulfiram-like reactions.
  • GLICLAZIDE – Concurrent use of ETHANOL and GLICLAZIDE may result in prolonged hypoglycemia and disulfiram-like reactions.
  • GLUTETHIMIDE – Concurrent use of GLUTETHIMIDE and ETHANOL may result in increased sedation.
  • GLYBURIDE – Concurrent use of GLYBURIDE and ETHANOL may result in prolonged hypoglycemia and disulfiram-like reactions.
  • GOSSYPOL – Concurrent use of GOSSYPOL and ETHANOL may result in delayed effects of gossypol and/or increased toxic effects of ethanol.
  • GRISEOFULVIN – Concurrent use of GRISEOFULVIN and ETHANOL may result in disulfiram-like reactions.
  • GUAR GUM – Concurrent use of GUAR GUM and ETHANOL may result in increased intoxication effects of ethanol.
  • GUARANA – Concurrent use of GUARANA and ETHANOL may result in increased risk of ethanol intoxication.
  • HYDROCODONE – Concurrent use of HYDROCODONE and ETHANOL may result in increased sedation.
  • HYDROMORPHONE – Concurrent use of HYDROMORPHONE and ETHANOL may result in increased sedation.
  • IMIPRAMINE – Concurrent use of IMIPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • INSULIN – Concurrent use of INSULIN and ETHANOL may result in increased hypoglycemia.
  • INSULIN LISPRO, HUMAN – Concurrent use of INSULIN LISPRO, HUMAN and ETHANOL and may result in increased hypoglycemia.
  • ISONIAZID – Concurrent use of ISONIAZID and ETHANOL may result in decreased isoniazid concentrations and disulfiram-like reactions.
  • ISOTRETINOIN – Concurrent use of ISOTRETINOIN and ETHANOL may result in disulfiram-like reactions.
  • KAVA – Concurrent use of KAVA and ETHANOL may result in increased CNS depression and/or increased risk of hepatotoxicity.
  • KETOCONAZOLE – Concurrent use of KETOCONAZOLE and ETHANOL may result in disulfiram-like reactions (flushing, vomiting, increased respiratory rate, and tachycardia).
  • LOFEPRAMINE – Concurrent use of LOFEPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • LORAZEPAM – Concurrent use of LORAZEPAM and ETHANOL may result in increased sedation.
  • MEPERIDINE – Concurrent use of MEPERIDINE and ETHANOL may result in increased sedation.
  • MEPHOBARBITAL – Concurrent use of MEPHOBARBITAL and ETHANOL may result in excessive CNS depression.
  • MEPROBAMATE – Concurrent use of MEPROBAMATE and ETHANOL may result in increased sedation.
  • MESORIDAZINE – Concurrent use of MESORIDAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • METFORMIN – Concurrent use of METFORMIN and ETHANOL may result in an increased risk of lactic acidosis.
  • METHADONE – Concurrent use of METHADONE and ETHANOL may result in increased sedation.
  • METHOCARBAMOL – Concurrent use of METHOCARBAMOL and ETHANOL may result nervous system side effects such as dizziness, drowsiness, and difficulty concentrating.
  • METHOHEXITAL – Concurrent use of METHOHEXITAL and ETHANOL may result in excessive CNS depression.
  • METHOTREXATE – Concurrent use of METHOTREXATE and ETHANOL may result in increased hepatotoxicity.
  • METHOTRIMEPRAZINE – Concurrent use of METHOTRIMEPRAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • METRONIDAZOLE – Concurrent use of METRONIDAZOLE and ETHANOL may result in disulfiram-like reactions (flushing, increased respiratory rate, tachycardia) or sudden death.
  • MIRTAZAPINE – Concurrent use of MIRTAZAPINE and ETHANOL may result in psychomotor impairment.
  • MORPHINE – Concurrent use of MORPHINE and ETHANOL may result in increased risk of respiratory depression, hypotension, profound sedation, or coma.
  • MORPHINE SULFATE LIPOSOME – Concurrent use of MORPHINE SULFATE LIPOSOME and ETHANOL may result in increased risk of respiratory depression, hypotension, profound sedation, or coma.
  • MOXALACTAM – Concurrent use of ETHANOL and MOXALACTAM may result in disulfiram-like reactions.
  • NEFAZODONE – Concurrent use of NEFAZODONE and ETHANOL may result in an increased risk of CNS side effects.
  • NIACIN – Concurrent use of NIACIN and ETHANOL may result in increased side effects of flushing and pruritus.
  • NILUTAMIDE – Concurrent use of NILUTAMIDE and ETHANOL may result in an increased risk of ethanol intolerance (facial flushing, malaise, and hypotension).
  • NITROGLYCERIN – Concurrent use of NITROGLYCERIN and ETHANOL may result in hypotension.
  • NORTRIPTYLINE – Concurrent use of NORTRIPTYLINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • OLANZAPINE – Concurrent use of OLANZAPINE and ETHANOL may result in excessive CNS depression.
  • OXYCODONE – Concurrent use of OXYCODONE and ETHANOL may result in increased sedation.
  • OXYMORPHONE – Concurrent use of OXYMORPHONE and ETHANOL may result in increased oxymorphone plasma levels (extended-release formulation) and additive CNS/ respiratory depression.
  • PARALDEHYDE – Concurrent use of PARALDEHYDE and ETHANOL may result in metabolic acidosis.
  • PAROXETINE – Concurrent use of PAROXETINE and ETHANOL may increase the risk of mental and motor-skill impairment.
  • PENNYROYAL – Concurrent use of PENNYROYAL and ETHANOL may result in elevated liver transaminases with or without concomitant hepatic damage.
  • PENTAZOCINE – Concurrent use of PENTAZOCINE and ETHANOL may result in increased sedation.
  • PERPHENAZINE – Concurrent use of PERPHENAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PHENELZINE – Concurrent use of PHENELZINE and ETHANOL may result in hypertension urgency or emergency.
  • PHENOBARBITAL – Concurrent use of PHENOBARBITAL and ETHANOL may result in excessive CNS depression.
  • PHENYTOIN – Concurrent use of PHENYTOIN and ETHANOL may result in decreased phenytoin serum concentrations, increased seizure potential, and additive CNS depressant effects.
  • PIPOTIAZINE – Concurrent use of PIPOTIAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PREGABALIN (LYRICA) – Concurrent use of PREGABALIN and ETHANOL increase the nervous system side effects of such as dizziness, drowsiness, and difficulty concentrating.
  • PRIMIDONE – Concurrent use of PRIMIDONE and ETHANOL may result in excessive CNS depression.
  • PROCARBAZINE – Concurrent use of PROCARBAZINE and ETHANOL may result in disulfiram-like reactions and increased sedation.
  • PROCHLORPERAZINE – Concurrent use of PROCHLORPERAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PROMAZINE – Concurrent use of PROMAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PROPIOMAZINE – Concurrent use of PROPIOMAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PROTRIPTYLINE – Concurrent use of PROTRIPTYLINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • QUETIAPINE – Concurrent use of QUETIAPINE and ETHANOL may result in potentiation of the cognitive and motor effects of alcohol.
  • REMDESIVIR – Concurrent use of REMDESIVIR and ETHANOL may result liver problems.
  • ROSUVASTATIN – Concurrent use of ROSUVASTATIN and ETHANOL may cause liver problems.
  • SECOBARBITAL – Concurrent use of SECOBARBITAL and ETHANOL may result in excessive CNS depression.
  • SERTRALINE – Concurrent use of SERTRALINE and ETHANOL may increase the risk of mental and motor-skill impairment.
  • SULFAMETHOXAZOLE – Concurrent use of SULFAMETHOXAZOLE and ETHANOL may result in disulfiram-like reactions (flushing, sweating, palpitations, and drowsiness).
  • TACROLIMUS – Concurrent use of TACROLIMUS and ETHANOL may result in alcohol-related flushing and rash.
  • TADALAFIL – Concurrent use of TADALAFIL and ETHANOL may result in an increased risk of hypotension and orthostatic signs and symptoms.
  • TEMAZEPAM – Concurrent use of TEMAZEPAM and ETHANOL may result in impaired psychomotor functions.
  • THIETHYLPERAZINE – Concurrent use of THIETHYLPERAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • THIEOPENTAL – Concurrent use of THIEOPENTAL and ETHANOL may result in excessive CNS depression.
  • THIORIDAZINE – Concurrent use of THIORIDAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • TIZANIDINE – Concurrent use of TIZANIDINE and ETHANOL may increase the risk of tizanidine adverse effects (excessive CNS depression).
  • TOLAZAMIDE – Concurrent use of TOLAZAMIDE and ETHANOL may result in prolonged hypoglycemia and disulfiram-like reactions.
  • TOLAZOLINE – Concurrent use of TOLAZOLINE and ETHANOL may result in disulfiram-like reactions.
  • TOLBUTAMIDE – Concurrent use of TOLBUTAMIDE and ETHANOL may result in prolonged hypoglycemia and disulfiram-like reactions.
  • TRAMADOL – Concurrent use of TRAMADOL and ETHANOL may increase the risk of excessive CNS depression.
  • TRANYLCYPROMINE – Concurrent use of TRANYLCYPROMINE and ETHANOL may result in hypertensive urgency or emergency.
  • TRIAZOLAM – Concurrent use of TRIAZOLAM and ETHANOL may result in increased sedation.
  • TRIFLUPERAZINE – Concurrent use of TRIFLUPERAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • TRIFLUPROMAZINE – Concurrent use of TRIFLUPROMAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • TRIMETHOPRIM – Concurrent use of ETHANOL and COTRIMOXAZOLE may result in disulfiram-like reactions.
  • TRIMIPRAMINE – Concurrent use of TRIMIPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • VALERIAN – Concurrent use of VALERIAN and ETHANOL may result in increased sedation.
  • VENLAFAXINE – Concurrent use of VENLAFAXINE and ETHANOL may result in an increased risk of CNS effects.
  • VERAPAMIL – Concurrent use of VERAPAMIL and ETHANOL may result in enhanced ethanol intoxication (impaired psychomotor functioning).
  • WARFARIN – Concurrent use of WARFARIN and ETHANOL may result in increased or decreased international normalized ratio (INR) or prothrombin time.
  • YOHIMBINE – Concurrent use of YOHIMBINE and ETHANOL may result in increased ethanol intoxication and increased anxiety and blood pressure.
  • ZALEPLON – Concurrent use of ZALEPLON and ETHANOL may result in impaired psychomotor functions.
  • ZOLPIDEM – Concurrent use of ZOLPIDEM and ETHANOL may result in increased sedation.

Read also: